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ABSTRACT
Flavin-containingmonooxygenase 3 (FMO3) is knownprimarily as an
enzyme involved in the metabolism of therapeutic drugs. On a daily
basis, however, we are exposed to one of the most abundant
substrates of the enzyme trimethylamine (TMA), which is released
fromvarious dietary components by the action of gut bacteria. FMO3
converts the odorous TMA to nonodorous TMA N-oxide (TMAO),
which is excreted in urine. Impaired FMO3 activity gives rise to the
inherited disorder primary trimethylaminuria (TMAU). Affected indi-
viduals cannot produce TMAO and, consequently, excrete large
amounts of TMA. A dysbiosis in gut bacteria can give rise to
secondary TMAU. Recently, there has been much interest in FMO3
and its catalytic product, TMAO, because TMAO has been implicated
in various conditions affecting health, including cardiovascular
disease, reverse cholesterol transport, and glucose and lipid
homeostasis. In this review, we consider the dietary components
that can give rise to TMA, the gut bacteria involved in the production
of TMA from dietary precursors, the metabolic reactions by which
bacteria produce and use TMA, and the enzymes that catalyze the
reactions. Also included is information on bacteria that produce
TMA in the oral cavity and vagina, two key microbiome niches that
can influence health. Finally, we discuss the importance of the
TMA/TMAO microbiome-host axis in health and disease, consid-
ering factors that affect bacterial production and host metabo-
lism of TMA, the involvement of TMAO and FMO3 in disease, and
the implications of the host-microbiome axis for management
of TMAU.
Introduction
Flavin-containing monooxygenases (FMOs) (EC 1.14.13.8) catalyze
the NADPH-dependent oxidative metabolism of a wide array of foreign
chemicals, including drugs, dietary-derived compounds, and environ-
mental pollutants (Krueger and Williams, 2005). Humans possess five
functional FMO genes: FMO1, 2, 3, 4, and 5 (Hernandez et al., 2004;
Phillips et al., 2007). The main site of expression of FMO3 is the liver
(Dolphin et al., 1996); however, high expression levels have also been
observed in the skin of certain individuals (Janmohamed et al., 2001).
The FMO3 gene is switched on in human liver at birth and can take
several years for the gene to attain maximum expression as the liver
develops to its full functional capacity (Koukouritaki et al., 2002).
Drug substrates for FMO3 include the antipsychotic olanzapine
(Söderberg et al., 2013), the antiestrogen tamoxifen (Parte and Kupfer,
2005), the gastroprokinetic agent itopride (Mushiroda et al., 2000), and
the H2-receptor antagonist cimetidine (Cashman et al., 1995). Substrates
undergoN- or S-oxygenation; generally, this is a detoxification route and
the products are excreted in urine, but some chemicals are converted to a
more active or toxic form (Krueger andWilliams, 2005). Retroreduction
of the oxygenated product can occur, creating a pool of drug that can be
recycled (Cashman, 2008). The importance of FMO3 in detoxification
and bioactivation of xenobiotics has recently been reviewed (Cruciani
et al., 2014). The FMO3 gene is highly polymorphic (Phillips et al.,
2007), and genetic variants that are common in the general population
are known to influence drug metabolism (Phillips et al., 2007; Söderberg
et al., 2013; Zhou et al., 2014).
FMO3 has an important relationship with the gut microbiome, with an
abundant nondrug substrate, trimethylamine (TMA), being derived from
dietary components by the action of gut microbes (Seim et al., 1985; Al-
Waiz et al., 1992). TMA is rapidly absorbed and is converted in the liver
to trimethylamine N-oxide (TMAO) (Higgins et al., 1972). Of the five
functional FMOs of humans (FMOs 1–5), only FMO3 effectively
catalyzes the conversion of TMA to TMAO (Lang et al., 1998). FMO3 is
thus an excellent example of a protein that participates in host-gut
microbiomemetabolic interactions (Nicholson et al., 2012). Rare genetic
variants of the FMO3 gene that abolish or severely impair activity of the
enzyme give rise to the inherited disorder primary trimethylaminuria
(TMAU) (Phillips and Shephard, 2008) because of inefficient conver-
sion of microbiome-derived odorous TMA to nonodorous TMAO.
Recently, there has been much interest in FMO3 and its catalytic
product TMAO. This is because TMAO has been implicated in various
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conditions affecting health, including cardiovascular disease, reverse
cholesterol transport, and glucose and lipid homeostasis (Wang et al.,
2011; Bennett et al., 2013; Koeth et al., 2013; Tang et al., 2013; Gao
et al., 2014; Obeid et al., 2016). The microbial origin of TMA is of great
interest as we begin to fully appreciate the importance of our micro-
biomes for health and well-being. Knowledge of the microbial species
that give rise to TMA would contribute greatly to our understanding of
the consequences for human health of the complex interrelationships of
diet, the microbiome, and the capacity for FMO3-catalyzed conversion
of TMA to TMAO.
In this review, we first describe the origins and metabolic fate of TMA
and outline the basis and consequences of TMAU.We then consider the
dietary components that can give rise to TMA, the gut bacteria involved
in the production of TMA from dietary precursors, the metabolic
reactions by which bacteria produce and use TMA, and the enzymes that
catalyze the reactions. Also included is information on bacteria that
produce TMA in the oral cavity and vagina, two key microbiome niches
that can influence health, and on noncommensal bacteria that pro-
duce TMA. Finally, we discuss the importance of the TMA/TMAO
microbiome-host axis in health and disease, considering factors that
affect bacterial production and host metabolism of TMA, the in-
volvement of TMAO and FMO3 in disease and the implications of the
host-microbiome axis for management of TMAU.
Origins and Metabolic Fate of TMA
The discovery and properties of TMA have been recently reviewed
(Mitchell and Smith, 2016). TMA is an indicator of food spoilage,
particularly of fish and milk. As early as the 1930s Beatty showed that
TMA was produced during fish spoilage (Beatty, 1938). The TMA is
derived from bacterially mediated reduction of TMAO (Barrett and
Kwan, 1985), which is present in large quantities in marine fish (Zhang
et al., 1999).
The requirement of bacterial action for the production of TMA from
the diet in vivo is demonstrated by the failure of germ-free rats fed
carnitine (Seim et al., 1985), or of germ-free or antibiotic-treated mice
fed a normal diet, to excrete TMA in their urine (Al-Waiz et al., 1992).
TMA is derived from the diet by microbial degradation of precursors
found in, for example, marine fish, eggs, offal, soya beans, peas, and red
meat (Zhang et al., 1999; Zeisel et al., 2003). Once liberated, TMA is
rapidly absorbed through the gut wall and transported to the liver, where
it is converted to nonodorous TMAO, which is then rapidly cleared in
the urine (Al-Waiz et al., 1987a). Analysis in vitro of heterologously
expressed FMOs revealed that, at physiologic pH, N-oxygenation of
TMA is catalyzed by FMO3, with a KM of 28 mM and an apparent kcat
of.30 minutes21 (Lang et al., 1998). Other FMOs are far less effective
in catalyzing this reaction: FMO1, FMO2, and FMO4, none of which is
expressed in adult human liver (Phillips et al., 2007), exhibit apparent
kcats of 0.1, 1.0, and 0.1minute
21, respectively, whereas FMO5, the only
other form of FMO expressed in the adult human liver (Phillips et al.,
2007), is unable to catalyze the reaction (Lang et al., 1998). FMO1,
which is expressed in human kidney (Dolphin et al., 1991), can catalyze
TMA N-oxygenation, with an apparent kcat of 5 minutes
21, but only at
substrate concentrations of 5 mM (Lang et al., 1998), which are unlikely
to be relevant for metabolism of TMA in vivo. The importance of FMO3
for the metabolism of TMA in vivo is demonstrated by the marked
reduction in the ability toN-oxygenate TMAof individuals homozygous
or compound heterozygous for mutations that severely impair FMO3
activity (Dolphin et al., 1997, 2000; Treacy et al., 1998).
In addition to N-oxygenation, rat liver microsomes carry out
demethylation of TMA, but the latter reaction is much less efficient
(Gut and Conney, 1991). Demethylation of TMA in rat liver was shown
to be catalyzed by a different FMO from that which catalyzes production
of the N-oxide (Gut and Conney, 1993). This FMO is probably FMO1,
whose gene is expressed in the liver of rodents and other mammals, but
not in adult human liver (Dolphin et al., 1991). In human volunteers, the
demethylation product was found in low amounts and only in those
dosed with high amounts of TMA (Al-Waiz, et al., 1987b). Conse-
quently, in humans FMO3-catalyzed N-oxygenation is by far the most
important route of metabolism of TMA.
Since microbial diversity studies have entered the era of high-
throughput sequencing and in silico analysis, more insight has been
gained into the composition of the human gut microbiota; however,
studies based on bacterial cultivation are still the main source for
information about themetabolic capacities of themicrobiota. Combining
what is being uncovered about the composition of the human microbiota
with what is known of the functional activity of its components enables
identification of microbial metabolic pathways by which TMA can be
produced or metabolized in the human gut.
TMAU, a Deficiency of FMO3
In humans, mutations that abolish or severely impair the activity of
FMO3 cause the inherited disorder primary TMAU (Dolphin et al., 1997;
Hernandez et al., 2003). Affected individuals have a severely reduced
ability to convert TMA to TMAO and, consequently, excrete large
amounts of odorous TMA in their urine, sweat, and breath (Ayesh et al.,
1993). Although the disorder has no overt physiologic effects on patient
health, it can have profound psychologic and social consequences,
resulting in a severe loss of quality of life, in extreme cases giving rise to
clinical depression and suicidal tendencies (Mitchell and Smith, 2001;
Shephard et al., 2015, [Phillips IR and Shephard EA. Primary
trimethylaminuria. GeneReviews at GeneTests: Medical Genetics In-
formation Resource (database online): University of Washington,
1997––2015 available at http://www.ncbi.nlm.nih.gov/books/NBK1103/,
updated 2015]. In terms of drug metabolism, TMAU individuals have
impaired metabolism of the FMO3 drug substrate benzydamine
(Mayatepek et al., 2004). Since the first discovery of a mutation known
to cause TMAU (Dolphin et al., 1997), many different causative
mutations have been identified (Phillips et al., 2007; Yamazaki and
Shimizu, 2013). A catalog of variants of the FMO3 gene and their effect
on the ability of FMO3 to catalyze the oxygenation of TMA and drug
substrates of the enzyme can be accessed at the FMO3 locus-specific
mutation database (http://databases.lovd.nl/shared/genes/FMO3).
Production of large amounts of TMA, as a result of gutmicrobial action,
exacerbates the symptoms of primary TMAU. In addition, overproduction
of TMA, as a consequence of a dysbiosis of the gut microbiome, can give
rise to a nongenetic form of the disorder, known as secondary TMAU
(Mitchell and Smith, 2001). Therefore, a better understanding of the
bacterial species that produce TMA in the gut may provide insights into
why some individuals develop secondary TMAU in the absence of
impaired N-oxygenation of TMA (Shimizu et al., 2014) and offers the
potential to develop improved strategies for the management and
treatment of both primary and secondary forms of the disorder.
Dietary Precursors of TMA and the Bacteria Involved in its
Production in the Gut
TMAO. TMAO, the oxygenated product of TMA, is itself a dietary
constituent that can give rise to TMA in the gut. Marine fish contain the
highest amounts of TMAO (up to 3 mg/g) of any food source (Mitchell
et al., 2002). The TMAO is thought to act as an osmolyte that allows
adaptation to changes in salinity (Pang et al., 1977) and hydrostatic
pressure (Zerbst-Boroffka et al., 2005). It is estimated that about 50% of
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consumed TMAO is not metabolized and passes through the body
unchanged to be excreted in the urine (Zhang et al., 1999). In the human
gut, the remainder of the TMAO is reduced to TMA by bacterial TMAO
reductase (EC 1.7.2.3) (Kwan and Barrett, 1983) (Fig. 1). Examples of
bacteria that produce TMA from TMAO are given in Table 1.
Choline. Choline is an essential dietary nutrient, which can function
as a precursor for the synthesis of phospholipids, including phosphati-
dylcholine, that are essential components of membranes, and of the
neurotransmitter acetylcholine. It is present in high quantities in a variety
of foodstuffs, for example, beef liver, cauliflower, and peanuts (Zeisel
et al., 2003), and high concentrations of free choline are present in
human milk and in soya bean–derived milk formulae (Zeisel, 1990).
Choline is usually ingested as lecithin (also known as phosphatidylcho-
line), however, in which the choline moiety is covalently bound to a
phosphatidate (a phosphoglycerol attached to two fatty acids) (Hirsch
et al., 1978). Interconversion of lecithin and choline is bidirectional,
conversion of lecithin to choline being catalyzed by phospholipase D
(EC 3.1.4.4) and the first step in the conversion of choline to lecithin by
choline kinase (EC 2.7.1.32) (Fig. 1).
Free choline is absorbed throughout the small intestine and is
subsequently integrated into cell membranes or actively taken up
by the liver, where it can be converted to betaine, phosphocholine, or
lecithin (Zeisel, 1990). High amounts of choline may exceed the
absorptive capacity and pass through to the large intestine, however,
where it is metabolized to methylamines by microbial action (Zeisel
et al., 1983). Choline is a quaternary ammonium compound containing a
trimethylammonium moiety. Thus, it can act as a precursor for TMA
(Zeisel et al., 1989; Chalmers et al., 2006). The bacterial conversion of
choline to TMA involves the cleavage of the carbon-nitrogen bond of
choline, producing TMA and acetaldehyde (Hayward and Stadtman,
1959). Craciun and Balskus (2012) proposed that a glycyl radical
enzyme CutC (EC 4.3.99.4), encoded by the bacterial choline utilization
gene cluster (cut), might act as a choline TMA-lyase to catalyze this
initial step in choline degradation (Fig. 1). This was confirmed by
demonstrating that deletion of cutC in Desulfovibrio desulfuricans
abolished the ability of the organism to produce TMA from choline.
Bioinformatics analysis revealed cutC homologs in 89 bacterial ge-
nomes. The homologs are not distributed evenly among the major
bacterial phyla of the human gut, being present in Firmicutes, Actino-
bacteria, and Proteobacteria spp. but absent from Bacteroidetes
(Craciun and Balskus, 2012). Table 1 shows bacteria known to be
associated with formation of TMA via choline degradation.
Carnitine. Carnitine plays a key role inmetabolism, being involved in
the transport of long-chain fatty acids from the cytosol into mitochondria.
Carnitine is a quaternary ammonium compound that can be synthesized
in the body from methionine and lysine, with its immediate precursor
being g-butyrobetaine (Feller and Rudman, 1988). L-carnitine is present
in red meat and dairy products (Feller and Rudman, 1988), and it is
estimated that the average nonvegetarian American consumes 100–
300mg/day (Feller and Rudman, 1988). Of dietary carnitine, about half is
absorbed from the intestine, and the other half is metabolized by gut flora,
eventually resulting in the excretion of TMAO and g-butyrobetaine in
urine and feces, respectively (Rebouche andChenard, 1991). Gut bacteria
are thought to cleave the 3-hydroperoxybutyryl moiety from L-carnitine
to produce TMA (Meadows and Wargo, 2015). This pathway has been
observed in several bacteria, including Serratia marascescens and
Acinetobacter calcoaceticus (Meadows and Wargo, 2015). Using
bioinformatics approaches, Zhu et al. (2014) identified a two-
component oxygenase/reductase Rieske-type enzyme, encoded by
cntAB, that catalyzed the formation of TMA from carnitine (see Fig. 1).
Fig. 1. Metabolic pathways for the production and metabolism of TMA by the human microbiota. TMA can be produced from TMAO in a reaction catalyzed by TMAO
reductase. Choline, either in its free form or released from lecithin (phosphatidylcholine), contributes to the formation of TMA directly, via the action of choline-TMA lyase,
encoded by the choline utilization cluster (cutC), or potentially indirectly, via conversion to betaine. Similarly, L-carnitine, present in red meat or derived from
g-butyrobetaine, contributes to TMA formation directly via the action of a Rieske-type carnitine reductase/oxidase (cntAB), or potentially indirectly, via conversion to
betaine or to g-butyrobetaine. Betaine can potentially contribute to TMA formation directly, via the action of a betaine reductase, or indirectly, via conversion to
dimethylglycine, which could be metabolized to TMA via a hypothetical decarboxylation. TMA can be produced from ergothioneine via the action of ergothionase. TMA
itself can be oxidized to TMAO, via the action of TMA monooxygenase. Asterisks represent multistep pathways. Bold text, TMA and its precursors and metabolites. Plain
text, enzymes that catalyze reactions in the pathways. Based on Zeisel, 1990; Kleber, 1997; Serra et al., 2002; Wood et al., 2010; Craciun and Balskus, 2012; Caspi et al.,
2014; Zhu et al., 2014.
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Both components are required for catalysis of electron transfer and
degradation of carnitine to TMA. Deletion of cntAB in A. calcoaceticus
rendered the microbe incapable of producing TMA. As is the case for
cutC in choline metabolism (Craciun and Balskus, 2012), cntAB is
distributed unevenly among the major bacterial phyla, being present in
Proteobacteria (mainly Gammaproteobacteria) and Firmicutes and
absent from Bacteroidetes spp. (Zhu et al., 2014).
In addition to generating TMA directly from L-carnitine, it has been
suggested that gut bacteria can also convert g-butyrobetaine to TMA.
Most studies consider g-butyrobetaine to be an intermediary metabolite
produced during the biosynthesis of L-carnitine, by a reaction catalyzed
by g-butyrobetaine hydroxylase (EC 1.14.11.1); however, the gut
microbiota may also be able to produce g-butyrobetaine from catabolism
of L-carnitine by a reaction catalyzed by g-butyrobetainyl-CoA:
carnitine-CoA transferase (EC 2.8.3.21) (Rebouche and Seim, 1998;
Caspi et al., 2014). Koeth et al. (2014) showed that g-butyrobetaine,
obtained through oral g-butyrobetaine or L-carnitine supplementation,
can bemetabolized bymicrobes to produce TMA and identified the gene
pair yeaW/yeaX as encoding an enzyme that catalyzes this reaction
in vitro. The enzyme, termed a carnitine TMA lyase (see Fig. 1), can also
catalyze production of TMAdirectly from choline, betaine, and carnitine
(Koeth et al., 2014). Table 1 shows bacteria known to be associated with
the formation of TMA via carnitine degradation.
Betaine. Betaine, or trimethylglycine, plays an important role as a
methyl donor in the betaine homocysteine methyltransferase pathway
(Obeid, 2013). It is present in high concentrations in various foodstuffs, for
example, wheat bran, wheat germ, and spinach (Zeisel et al., 2003). The
daily intake of betaine varies from;30–400 mg/d (Obeid, 2013). Betaine
TABLE 1
Bacteria that produce trimethylamine (TMA) from various substrates
Phylum Genus or Species References
TMA N-oxide
Actinobacteria Micrococcus Robinson et al., 1952
Mobiluncus Cruden and Galask, 1988
Firmicutes Bacillus Robinson et al., 1952
Clostridium Robinson et al., 1952
Staphylococcus Robinson et al., 1952
Sarcina Robinson et al., 1952
Streptococcus Robinson et al., 1952
Proteobacteria Alcaligenes Robinson et al., 1952
Campylobacter Sellars et al., 2002
Citrobacter Lin and Hurng, 1989
Escherichia Robinson et al., 1952; Ishimoto and Shimokawa, 1978; Cox and Knight, 1981; Takagi et al., 1981;
Easter et al., 1982; Lin and Hurng, 1989; Denby et al., 2015
Proteus Robinson et al., 1952; Strøm et al., 1979; Stenberg et al., 1982
Pseudomonas Robinson et al., 1952; Lee et al., 1977; Easter et al., 1982; Chen et al., 2011
Choline
Actinobacteria Mobiluncus Cruden and Galask, 1988
Olsenella Craciun and Balskus, 2012; Martínez-del Campo et al., 2015
Bacteroidetes Bacteroides Cruden and Galask, 1988
Firmicutes Anaerococcus Craciun and Balskus, 2012; Romano et al., 2015
Clostridium Robinson et al., 1952; Bradbeer, 1965; Fiebig and Gottschalk, 1983; Möller et al., 1986; Craciun and
Balskus, 2012; Martínez-del Campo et al., 2015; Romano et al., 2015
Desulfitobacterium Craciun and Balskus, 2012
Enterococcus Simenhoff et al., 1976
Streptococcus Robinson et al., 1952; Simenhoff et al., 1976; Chao and Zeisel, 1990; Craciun and Balskus, 2012;
Martínez-del Campo et al., 2015
Proteobacteria Desulfovibrioa Hayward and Stadtman, 1959, 1960; Baker et al., 1962; Bradbeer, 1965; Fiebig and Gottschalk, 1983;
Craciun and Balskus, 2012
Edwardsiella Romano et al., 2015
Enterobacterb Eddy, 1953; Craciun and Balskus, 2012
Escherichia Craciun and Balskus, 2012; Martínez-del Campo et al., 2015; Romano et al., 2015
Klebsiellab Eddy, 1953; Craciun and Balskus, 2012; Kuka et al., 2014; Kalnins et al., 2015;
Martínez-del Campo et al., 2015
Proteus Seim et al., 1982a; Craciun and Balskus, 2012; Kuka et al., 2014; Martínez-del Campo et al., 2015;
Romano et al., 2015
Providencia Craciun and Balskus, 2012; Romano et al., 2015
Pseudomonas Robinson et al., 1952; Kleber et al., 1978
Yokenella Craciun and Balskus, 2012
Carnitine
Proteobacteria Acinetobacter Kleber et al., 1977; Seim et al., 1982b; Miura-Fraboni et al., 1982; Ditullio et al., 1994; Zhu et al., 2014
Citrobacter Zhu et al., 2014
Escherichia Zhu et al., 2014
Klebsiella Kuka et al., 2014; Zhu et al., 2014
Proteus Seim et al., 1982a
Pseudomonas Kleber et al., 1978; Miura-Fraboni et al., 1982
Betaine
Firmicutes Clostridium Naumann et al., 1983; Möller et al., 1986
Eubacterium Zindel et al., 1988; Hormann and Andreesen, 1989
Sporomusa Möller et al., 1986; Hormann and Andreesen, 1989
Ergothioneine
Proteobacteria Alcaligenes Yanasugondha and Appleman, 1957; Kelly and Appleman, 1961
Escherichia Wolff, 1962
aSynonym: Vibrio cholincus.
bInitially observed as Aerobacter but reassigned to genera Enterobacter and Klebsiella.
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can also be biosynthesized, in both the human host and in gut bacteria, by
oxidation of choline or carnitine. The oxidation of choline to betaine
involves an intermediate conversion to betaine aldehyde, catalyzed by
choline dehydrogenase (EC 1.1.99.1), which in turn is converted to betaine
in a reaction catalyzed by betaine aldehyde dehydrogenase (EC 1.2.1.8)
(Andresen et al., 1988) (Fig. 1). L-carnitine can be converted to betaine via
a multistep pathway, the first reaction of which is catalyzed by L-carnitine
dehydrogenase (EC 1.1.108) (Meadows and Wargo, 2015) (Fig. 1).
There are several catabolic pathways for betaine (Fig. 1). One involves
demethylation of betaine to dimethylglycine, in a reaction catalyzed by
glycine betaine transmethylase (EC 2.1.1.5) (Wood et al., 2010; Caspi
et al., 2014). Dimethylglycine could be metabolized to TMA via a
hypothetical decarboxylation (Wood et al., 2010). Betaine can also
function as an electron acceptor in a coupled reduction-oxidation reaction
(i.e., Stickland reaction), catalyzed by betaine reductase (EC 1.21.4.4), in
which it is reduced and cleaved to produce TMA and acetate (Naumann
et al., 1983). Table 1 shows bacteria associated with the formation of
TMA through betaine degradation.
Ergothioneine. Ergothioneine, a biogenic amine, is a derivative of
histidine. Production of ergothioneine is common among fungi and in
certain bacteria, such as Actinobacteria, Cyanobacteria, Bacteroidetes,
and Proteobacteria spp. (Seebeck, 2010; Pfeiffer et al., 2011).
Ergothioneine is also present in mammals, where it is concentrated
in specific tissues or cells, such as kidney, liver, and erythrocytes
(Cheah and Halliwell, 2012). Mammals lack the ability to synthesize
ergothioneine, however, and humans derive the compound exclusively
from dietary sources such as mushrooms (bolete and oyster), some meat
products (kidney and liver), and some plant products (e.g., black beans,
red beans, oat bran) (Ey et al., 2007). The biologic role of ergothioneine
in humans is unknown, but it is thought to have antioxidant and
cytoprotectant properties (Cheah and Halliwell, 2012). When grown on
ergothioneine, some bacteria are able to use the compound as a sole
source of nitrogen, carbon, or energy. The degradation of ergothioneine,
catalyzed by ergothionase (EC 4.3.3.-), yields TMA and thiolurocanic
acid (Muramatsu et al., 2013) (Fig. 1). Table 1 shows bacteria associated
with the production of TMA from ergothioneine.
Metabolism of TMA by Gut Bacteria
Two pathways for microbial metabolism of TMA have been proposed
(Colby and Zatman, 1973). One involves the sequential oxygenation of
TMA and demethylation of its oxygenated form to yield dimethylamine
and formaldehyde (Fig. 2). This pathway is mediated by a trimethyl-
amine monooxygenase (EC 1.14.13.148) and a trimethylamine-oxide
aldolase (EC 4.1.2.32) and has been demonstrated to occur in
Pseudomonas aminovorans (Large et al., 1972; Boulton et al., 1974),
Bacillus (Myers and Zatman, 1971), and methylotrophs such as
Hyphomicrobium (Meiberg et al., 1980; Barrett and Kwan, 1985). The
other pathway involves an energetically more favorable direct N-
demethylation of trimethylamine to give dimethylamine and formalde-
hyde, catalyzed by trimethylamine dehydrogenase (EC 1.5.8.2) (Colby
and Zatman, 1973) (Fig. 2). In methylotrophs, dimethylamine is further
metabolized to methylamine (MA) and then ammonia, each step
producing formaldehyde, by reactions catalyzed by dimethylamine
dehydrogenase (EC 1.5.8.1) and MA dehydrogenase (amicyanin) (EC
1.4.9.1), respectively (Asatoor and Simenhoff, 1965; Colby and Zatman,
1973; Barrett and Kwan, 1985) (Fig. 2).
Oral and Vaginal Microbiota
The gut, although the major site of TMA production, is not the only
nichewith resident bacterial species capable of producing TMA. Patients
with TMAU report a strange taste in their mouth and may suffer from
bad breath (Mitchell, 2005; Wise et al., 2011). Halitosis is primarily the
result of microbial production of volatile sulfur compounds, short-chain
fatty acids, and diamines (Scully and Greenman, 2012); however, TMA
can also contribute to foul breath odor, either being produced in situ from
choline (Chao and Zeisel, 1990) or as a result of TMA circulatory
overload (Mitchell, 2005). One specific member of the oral microbiota,
Streptococcus sanguis I, has been shown to form TMA from choline,
presumably as a result of enzymatic action on the carbon-nitrogen bond
of choline (Chao and Zeisel, 1990).
In bacterial vaginosis, the vaginal discharge has a prominent fishy
odor owing to elevated amounts of TMA (Brand and Galask, 1986;
Oakley et al., 2008). Vaginal TMA can arise from the degradation of
carnitine and choline or from the reduction of TMAO produced by some
methylotrophs (Barrett and Kwan, 1985) (see previous discussion).
Normally, Lactobacillus and Atopobium spp. are the predominant
members of the vaginal microbiota. In cases of bacterial vaginosis,
Lactobacillus appears to be replaced by genera such as Gardnerella,
Pseudomonas, Mobiluncus, Bacteroides, Prevotella, Porphyromonas,
and Streptococcus (Cruden and Galask, 1988; Hyman et al., 2005;
Armougom and Raoult, 2009). Thus, compared with a healthy vaginal
microbiota, bacterial vaginosis is associated with a higher proportion of
Actinobacteria andBacteroidetes phyla and a lower proportion ofFirmicutes
(Oakley et al., 2008).Mobiluncus strains isolated from patients with bacterial
vaginosis can produce TMA by reduction of TMAO (Cruden and Galask,
1988; Wolrath et al., 2002) and, to a lesser extent, by degradation of choline
(Cruden and Galask, 1988). One Bacteroides isolate has also been shown to
produce TMA from choline (Cruden and Galask, 1988).
As described already, methylotrophs can produce MA, their main
source of energy, from TMA (Barrett and Kwan, 1985). Thus, excess
production of TMA in the mouth and vagina in halitosis and bacterial
vaginosis, respectively, would provide environments favorable to
methylotrophs. Several methylotrophic strains have been shown to be
present in the microbiota of the human mouth (Anesti et al., 2005).
Fig. 2. Metabolism of TMA by gut bacteria. TMA can be metabolized to TMAO,
which is subsequently converted to dimethylamine (DMA) and formaldehyde.
TMA can be converted by direct N-demethylation to DMA and formaldehyde. In
methylotrophs, DMA can be further converted to MA and then ammonia, each
step producing formaldehyde. Reactions are catalyzed by 1, TMA monooxyge-
nase; 2, trimethylamine-oxide aldolase; 3, trimethylamine dehydrogenase; 4,
dimethylamine dehydrogenase and 5, methylamine dehydrogenase (amicyanin).
Based on Colby and Zatman (1973). Names of enzymes are those currently
recommended by the Enzyme Commission, and some differ from those given in
the original papers.
TMA/TMAO, an FMO3-Mediated Host-Microbiome Metabolic Axis 1843
 at A
SPET Journals on N
ovem
ber 9, 2017
dm
d.aspetjournals.org
D
ow
nloaded from
 
Noncommensal Bacteria Able to Produce TMA
In humans, TMA-producing bacteria are not limited to the commensal
flora. Some noncommensal bacteria, including pathogens such as
Aeromonas, Burkholderia, Campylobacter, Salmonella, Shigella and
Vibrio, are able to form TMA (Wood and Keeping, 1944; Lerke et al.,
1965; Kwan and Barrett, 1983; Muramatsu et al., 2013) from TMAO,
carnitine, choline or ergothioneine. Noncommensal bacteria that pro-
duce TMA are shown in Table 2.
TMA/TMAO Host-Microbiome Metabolic Axis in Health and
Disease
TMA is produced from dietary precursors by the action of gut bacteria
and is metabolized to TMAO in the liver by a reaction catalyzed by
FMO3 (Fig. 3A).
Factors Affecting the Production of TMA from Dietary
Precursors. Production of TMA by microbial gut action is dependent
on the type and amount of TMA precursors in the diet, the foodstuffs in
which they are present, and the identity and relative abundance of
bacterial species present in the gut.
A study of healthy male volunteers found that, in each individual,
there were striking differences in the amount of TMA produced from
various dietary precursors (15 mmol) administered orally in pure form,
as judged by urinary analysis of TMA and TMA N-oxide (Zhang et al.,
1999). TMAO was the best source, with almost 80% of the dose being
excreted in urine as TMA or TMA N-oxide, followed by choline (about
60%) and carnitine (about 30%); however, betaine, creatinine and
lecithin, although containing a trimethylamino moiety, elicited no
significant increase in urinary excretion of either TMA or TMAO in any
of the individuals studied. In addition, comparison of the amounts of
TMA released by chemical hydrolysis of foods in vitro with those
obtained from biologic digestion of the foods in vivo revealed that
marine fish and seafood are by far the best source of dietary-derived
TMA, with up to 85% of the TMA content of the food being liberated by
biologic digestion. In contrast, red meat, despite its high content of
carnitine, a good source of TMA when ingested in its pure form, is a
relatively poor source of TMA, with only 5% and 12% of the TMA
content of lamb and beef, respectively, being released by biologic
digestion (Zhang et al., 1999; Mitchell et al., 2002). These studies,
although on a relatively small number of individuals, indicate that
amounts of TMA derived from digestion of a particular food cannot be
accurately predicted on the basis of the content of the trimethylamino
moiety in the food.
The human gut microbiome displays considerable interindividual and
intraindividual variation (Caporaso et al., 2011; Yatsunenko et al.,
2012). Such variation would be expected to influence the relative yield
of TMA produced from various foodstuffs. The identity and relative
abundance of gut microbes can be investigated by bacterial cultivation;
however, this approach is limited by the inability to culture some
members of the microbiota (Zoetendal et al., 2008). Although sequence
determination of 16S rDNA is able to identify most major phyla, it is
thought to underestimate Actinobacteria (Tottey et al., 2013), which are
known to produce TMA from TMAO and choline (Table 1). The
development of next-generation deep-sequencing methods will provide
more accurate knowledge of the identity and relative abundance of
bacterial species present in the human gut.
In addition to the identification of bacteria, it is necessary to establish
their functionwith respect to their ability to produce or metabolize TMA.
There are several pathways resulting in the formation of TMA (Fig. 1),
and production of TMA is not exclusive to any one bacterial phylum.
Current taxonomic classification is based on DNA sequence rather
than on bacterial function. Thus, it is possible for a bacterial species
TABLE 2
Noncommensal bacteria that produce trimethylamine (TMA) from various substrates
Phylum Genus or Species References
TMA N-oxide
Bacteroidetes Flavobacterium Robinson et al., 1952
Proteobacteria Achromobacter Campbell and Williams, 1951; Lerke et al., 1965
Aeromonas Lerke et al., 1965; Lin and Hurng, 1989
Alteromonas Lerke et al., 1965; Lee et al., 1977; Easter et al., 1982, 1983;
Ringø et al., 1984
Photobacterium Dalgaard, 1995
Rhodopseudomonas Madigan and Gest, 1979; Cox et al., 1980; Madigan et al., 1980
Salmonella Kwan and Barrett, 1983
Shewanellaa Dalgaard, 1995; López-Caballero et al., 2001; Shaw and Shewan, 1968)
Shigella Wood et al., 1943; Campbell and Williams, 1951
Vibrio Lerke et al., 1965; Unemoto et al., 1965; Shaw and Shewan, 1968;
Easter et al., 1982
Betaine
Firmicutes Haloanaerobacter Mouné et al., 1999
Proteobacteria Desulfuromonas Heijthuijsen and Hansen, 1989
Carnitine
Proteobacteria Achromobacter Zhu et al., 2014
Serratia Unemoto et al., 1966
Shigella Zhu et al., 2014
Choline
Proteobacteria Achromobacter Campbell and Williams, 1951
Shigella Wood and Keeping, 1944
Ergothioneine
Proteobacteria Burkholderia Muramatsu et al., 2013
Campylobacter Muramatsu et al., 2013
Stigmatella Muramatsu et al., 2013
Sinorhizobiumb Muramatsu et al., 2013
aBasionym: Alteromonas putrefaciens.
bBasionym: Rhizobium meliloti.
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belonging to one phylum to share metabolic activity with species
belonging to other phyla but not with other members of the same
phylum. Based on DNA sequence analysis, Bacteroidetes lack the cutC
and cntAB genes (Craciun and Balskus, 2012; Zhu et al., 2014) and, thus,
would appear unlikely to produce TMA from choline or carnitine;
however, in vivo cultivation studies show that some members of the
Bacteroidetes phylum are able to produce TMA from choline (Cruden
and Galask, 1988). In addition, not all strains that encode CutC are able
to produce TMA from choline, and even within the same species, strains
may differ in the ability to convert choline to TMA (Romano et al.,
2015). Thus, one should be cautious when using phylogeny as the sole
predictor of microbial TMA production or as an indicator of metabolic
capacity in general.
The lack of any increase in urinary TMA or TMAO, in response to
ingestion of betaine, in any of the individuals studied (Zhang et al., 1999;
Mitchell et al., 2002) (see preceding) indicates that the metabolic
reactions that produce TMA from betaine, either directly or via
dimethylglycine (Fig. 1), or the bacteria in which these reactions occur,
are not prevalent, at least in healthyBritishmen. The inability to generate
TMA from betaine also indicates that the potential routes for production
of TMA from choline or carnitine, via their initial conversion to betaine
(Fig. 1), do not make significant contributions to TMA production.
Factors affecting the production of TMA in the gut are summarized in
Fig. 3B.
Factors Influencing TMA Metabolism in the Host. Individuals
who consume a ‘typical’ Western diet will produce, via the action of
gut bacteria, about 50 mg of TMA/day (Walker and Wevers, 2012),
most of which (;95%) is converted to TMAO, which is excreted in
the urine (Mitchell and Smith, 2001). Thus, FMO3 is efficient in
dealing with a relatively high substrate load; however, even
individuals with good FMO3 catalytic capacity can become over-
loaded when challenged with large amounts of TMA precursors (Al-
Waiz et al., 1989; Mitchell and Smith, 2016). Dietary components
such as indoles, found in members of the Cruciferare family of
vegetables, have been shown to inhibit the activity of FMO3 in vitro
and, in a human study, to decrease the amount of TMAO produced as
a percentage of total TMA (TMA + TMAO) excreted (Cashman
et al., 1999).
Gender-specific effects in humans also influence the amount of
urinary TMA. In a study of men over a 30-day period, only a slight
variation in the amount of TMA excreted in the urine was seen when
expressed as a percentage of total TMA (TMA + TMAO) (Mitchell and
Smith, 2010). In contrast, women excreted increased urinary TMA
around the time of menstruation, and this increase lasted for ;7 days
(Mitchell and Smith, 2010). This increase in TMA excretion is the result
of a reduction in its metabolism to TMAO, which is thought to be due to
the action of female sex hormones decreasing the expression of the
FMO3 gene (Coecke et al., 1998). In men, high levels of testosterone
also have been found to reduce FMO3 capacity (Ayesh et al., 1995).
Primary TMAU is known to be due to mutations that result in
impaired catalytic activity of FMO3 and, hence, increased urinary
excretion of TMA; however, other situations also cause an increase in
TMA excretion (Mitchell and Smith, 2016), for example, impaired liver
function (Mitchell et al., 1999), impaired renal function (Bain et al.,
2006; Hur et al., 2012; Hao et al., 2013), and pancreatic cancer
(Navaneethan et al., 2014).
Fig. 3. The origin of TMA and TMAO and factors that
influence their production. (A) The production and metabolic
fate of TMA. TMA is produced from dietary precursors by
the action of gut bacteria. TMA can be metabolized by gut
bacteria to TMAO and dimethylamine (DMA) (see Fig. 2) or
absorbed and converted in the liver to TMAO in a reaction
catalyzed by FMO3. TMAO and any unmetabolized TMA
will enter the plasma and subsequently will be excreted in
urine. (B) Factors affecting the production of TMA in the gut.
The amount of TMA produced is dependent on the nature and
quantity of dietary precursors and the relative abundance of
TMA-producing and TMA-metabolizing bacteria. (C) Factors
influencing TMA metabolism in the host. The metabolism of
TMA to TMAO in liver is dependent on the amount and
activity of FMO3. The abundance and activity of FMO3 can
be increased as a consequence of genetic variation, resulting
in an increase in the ratio of TMAO:TMA. The amount and
activity of FMO3 can be decreased by genetic variation,
hormones, inhibitors, and disease, resulting in a decrease in
the ratio of TMAO:TMA.
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The expression of the FMO3 gene in human liver is switched on
between birth and 2 years of age and increases during childhood and
adolescence, reaching its maximum level in adults (Koukouritaki et al.,
2002). Thus, in comparison with adults, children, especially infants,
have lower amounts of FMO3. Consequently, they are less able to
metabolize TMA to TMAO and, thus, may exhibit symptoms of
transient childhood TMAU, particularly if they are homozygous
for two common polymorphic variants of FMO3, c.472G.A [p.
(Glu158Lys)], and c.923A.G [p.(Glu308Gly)], which moderately
reduce catalytic activity (Zschocke and Mayatepek, 2000). One poly-
morphic variant of FMO3, c.1079T . C [p.(Leu360Pro)], increases
catalytic activity (Lattard et al., 2003); however, the variant has been
detected only in African populations and then at low frequency.
Polymorphic promoter-region variants of the FMO3 gene have been
identified that severely reduce transcription in vitro, whereas others
increase transcription (Koukouritaki et al., 2005), but the impact of these
variants on expression of FMO3 in vivo has not been validated. Factors
influencing the metabolism of TMA to TMAO in the liver are
summarized in Fig. 3C.
Potential Involvement of TMAO and FMO3 in Disease. Recently,
TMAO has been implicated in a number of disease states as a cause,
consequence, or biomarker of the disease. It has been suggested that an
increase in the plasma concentration of TMAO, as a consequence of
production of TMA from dietary supplements of choline, carnitine, or
TMAO by gut bacteria and its subsequent oxygenation by FMO3 in the
liver, increases the risk of cardiovascular disease (Wang et al., 2011;
Bennett et al., 2013; Koeth et al., 2013; Tang et al., 2013; Obeid et al.,
2016). TMAO has also been implicated in chronic kidney disease (Tang
et al., 2015), colorectal cancer (Xu et al., 2015), and in impaired glucose
tolerance inmice fed a high-fat diet and a TMAO supplement (Gao et al.,
2014); however, lower plasma concentrations of TMAO have been
associated with inflammatory bowel disease and with active versus
inactive ulcerative colitis (Wilson et al., 2015).
A number of roles for FMO3 itself in health and disease have been
suggested, based on studies using mice. Knockdown of FMO3 mRNA
by antisense oligonucleotides in female low-density lipoprotein
receptor-knockout mice suggests a role for FMO3 inmodulating glucose
and lipid homeostasis (Shih et al., 2015). FMO3 has also been identified
as a target of insulin (Miao et al., 2015): Fmo3 expression wasmore than
1000-fold higher in the livers of male liver insulin receptor-knockout
(LIRKO) mice compared with littermate controls, whereas knockdown
of FMO3 in LIRKO mice reduced expression of the transcription factor
forkhead box O1 and prevented the development of hyperglycemia,
hyperlipidemia, and atherosclerosis. Other suggested roles for FMO3
include involvement in cholesterol metabolism and reverse cholesterol
transport (Bennett et al., 2013; Warrier et al., 2015).
The implication that TMAO itself is a causative factor for cardiovas-
cular and other diseases is controversial. A recent review considers in
detail the physiologic roles of TMAO and the evidence for and against
TMAO being detrimental for health (Ufnal et al., 2015). The link
between TMAO levels and atherosclerosis seems counterintuitive
considering that consumption of marine fish, the richest dietary source
of TMAO (Zhang et al., 1999), is firmly associated with a reduction in
the incidence of cardiovascular disease (Takata et al., 2013). Other
studies found no correlation of TMAO levels with biomarkers of
cardiovascular disease. For instance, elevated levels of TMAO caused
no increase in C-reactive protein or low-density lipoprotein, in either
mouse or human plasma (Miller et al., 2014), and a study of oral
carnitine supplementation of patients undergoing hemodialysis showed
that, although TMAO was increased, markers of vascular injury were
reduced, and, consequently, supplementation with carnitine is thought to
be beneficial for these patients (Fukami et al., 2015). Indeed, carnitine
has proven efficacious for treatment of cardiovascular disease (Flanagan
et al., 2010).
Many of the studies that implicate TMAO as a causative factor in
cardiovascular disease are based on studies of mice and involve chronic
administration of pure TMA precursors in amounts that far exceed those
present either in a normal diet or in therapeutic supplements. Indeed, in
the case of carnitine, significant increases in dietary-derived TMA in
humans are obtained only with high chronic dose regimens (Holmes
et al., 1997). Consequently, normal dietary conditions or moderate
supplementation are unlikely to elicit the production of the amounts of
TMAO that have been associated with cardiovascular disease.
When designing experimental studies on mice and extrapolating the
results of these experiments to humans, it is important to appreciate that
there is a species-specific gender difference in the expression of FMO3
between humans and mice. At about 6 weeks of age, expression of the
Fmo3 gene is switched off in the liver of male, but not of female, mice
(Falls et al., 1995; Janmohamed et al., 2004). After this age, male mice
produce no hepatic FMO3 protein; thus, in comparison with female
mice, produce far less TMAO and, consequently, excrete larger amounts
of TMA in their urine. Despite this marked gender-specific difference,
there is no obvious difference in the propensity of male and female wild-
type mice to develop cardiovascular disease. A study of adult C57BL/6
wild-type mice found no difference in plasma glucose between male and
female mice and showed that females, which express hepatic FMO3 and
thus produce TMAO, have lower plasma cholesterol than males
(Gonzalez Malagon et al., 2015). A further complication is that humans
do not express FMO1 in liver (Dolphin et al., 1991; Phillips et al., 1995;
Koukouritaki et al., 2002), in marked contrast to all other mammals
investigated, in which FMO1 is a major form of FMO in this tissue
(Hernandez et al., 2004).
Evidence has shown that the FMO3 gene of humans has been the
subject of balancing natural selection (Allerston et al., 2007). Three
alleles appear to be targets for selection: the ancestral allele, an allele
encoding an enzyme with moderately reduced catalytic activity, and one
associated with increased promoter activity. Heterozygotes for a loss-of-
function mutation of FMO3, despite having a 50% reduction of FMO3
activity, are able to convert ;95% of a normal dietary load of TMA to
TMAO and, in this respect, are indistinguishable from individuals
homozygous for a functional FMO3 gene (Al-Waiz et al., 1987c). This
finding indicates that it is unlikely that the decreased capacity to produce
TMAO was the evolutionary advantage that drove selection of the allele
encoding a FMO3 with reduced activity.
An alternative explanation for high levels of TMAO associated with
cardiovascular disease is that the concentrations are indicative of
dysfunction(s) elsewhere and that TMAO is not the mediator but is
merely a marker of the disease (Ufnal et al., 2015). In mice, TMAO
increases in response to a high-fat diet (Yang et al., 2014). High-fat diets
change the composition of the gut microbiome to one associated with
obesity and its related health problems. These changes increase the
relative proportion of Firmicutes (Ley et al., 2006), a phylum whose
members contribute to TMA production, and decrease that of Bacter-
iodetes, a phylum that contributes very little to TMA production
(Table 1). Elevated plasma and urinary TMAO, therefore, may be a
marker for a gut microbiome that has deleterious effects on health and
not itself a causative factor. Indeed, atherosclerosis indices were
increased in mice in response to a high-fat diet, but dietary supplemen-
tation with TMAO had the opposite effect, significantly decreasing
atherosclerosis indices (Gao et al., 2014). It is important to note that no
health benefits have been reported for TMAU individuals, who produce
very low amounts of TMAO because of their impaired FMO3 activity.
Implications for TMAU. One disorder known unambiguously to be
associated with FMO3 is primary TMAU, caused by mutations in the
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FMO3 gene (Dolphin et al., 1997) (see previous discussion), a condition
characterized by secretion of excessive amounts of odorous TMA
(Mitchell and Smith, 2001). There is no cure for the disorder, and current
treatment is aimed at management of the symptoms. The main approach
is restriction of dietary precursors of TMA. Although humans may
possess gut bacteria capable of producing TMA from choline and
carnitine when administered in pure form, they are much less able to
access these precursors from foodstuffs such as red meat and peanuts
(Zhang et al., 1999; Mitchell et al., 2002). In contrast, the precursor
TMAO is efficiently extracted in the gut from marine fish and seafood
(Zhang et al., 1999; Mitchell et al., 2002). These results have
implications for dietary management of TMAU, indicating that the
most important foodstuffs to avoid are marine fish and seafood and those
that contain free choline, such as soya bean-derived milk, whereas red
meat would contribute less to TMA load.
Another strategy would be manipulation of gut flora to reduce the
proportion of bacteria that produce TMA and increase the proportion of
those that metabolize TMA. Although TMA-producing species are
widely distributed across bacterial phyla, they are more common in
Firmicutes and relatively scarce in Bacteriodetes (Table 1). Conse-
quently, decreasing the ratio of Firmicutes to Bacteriodetes would be
expected to reduce production of TMA from dietary precursors. A low
ratio of Firmicutes to Bacteriodetes is associated with a healthy
microbiome (Ley et al., 2006); thus, such alteration of the gut micro-
biome would promote general health as well as aiding in the manage-
ment of TMAU.
One approach to altering the composition of the gut microbiome is
exogenous supplementation with beneficial species (probiotics); how-
ever, a recent study found that the multistrain probiotic VSL#3 had no
effect on the increase in plasma concentration of TMAO in individuals
fed a high-fat diet (Boutagy et al., 2015). Another proposal is the
therapeutic use of methylotrophic strains of archaea (archaebiotics) that
use TMA as an energy source (Brugère et al., 2014), although this has
yet to be tried.
A further possibility is the selective inhibition of bacterial enzymes
that catalyze reactions involved in the production of TMA. Candidates
are TMA reductase, CutC, and CntAB, which respectively catalyze
TMA production from TMAO, choline and carnitine (Fig. 1). For
instance, 3,3-dimethyl-1-butanol, a structural analog of choline, inhibits
microbial CutC and reduces the plasma concentration of TMAO in mice
fed diets rich in choline or carnitine (Wang et al., 2015); however, most
of the choline eaten by humans is in the form of lecithin, which is not a
good dietary source of TMA (Zhang et al., 1999); thus, the efficacy of
the inhibitor for reducing TMA production in human gut is unclear.
Conclusions
TMA is derived from dietary precursors via the action of gut
bacteria. The amount of TMA absorbed by humans is determined by
the type and quantity of dietary precursors and the composition of the
gut microbiome, in particular with respect to bacteria that produce or
consume TMA. TMAO, choline, and carnitine, but not betaine,
creatinine, and lecithin, are good sources of TMA in their pure form.
Marine fish and seafood are the best food sources of TMA, but red
meat, despite its high content of carnitine, is a poor source.
Consequently, it is not possible to predict the amount of TMA that
will be derived from a particular food on the basis of the content of the
trimethylamino moiety in the food. Bacteria from several phyla
produce TMA from dietary precursors but are more common in
Firmicutes and scarce in Bacteriodetes.
FMO3, its microbiome-derived substrate TMA and the product of
FMO3 catalysis, TMAO, have been implicated in a number of disease
states. That mutations of FMO3 cause the inherited disorder primary
TMAU, through a failure to convert TMA to TMAO, is well established;
however, TMAO has attracted increasing notoriety as a molecule that
might be harmful for health. The evidence for this is controversial, and
there are studies for and against the importance of TMAO in conditions
affecting health. No known health benefits have been reported as a
consequence of the lack or low production of TMAO in primary TMAU
patients. Large, well-designed clinical studies are needed to examine
whether changes in the plasma concentration of TMAO in non-TMAU
patients are a consequence of the diet of an individual or of the bacterial
species that populate their gut, which may well change in response to the
health status of an individual. It is intriguing that consumption of marine
fish, the richest dietary source of TMAO, is beneficial, not harmful, to
cardiovascular health.
In addition, FMO3 has a wide range of drug substrates. This, together
with its intimate relationship with the microbiome-produced FMO3
substrate TMA, indicates that changes in composition of the gut
microbiome might influence both the metabolism and efficacy of
therapeutic drugs.
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